Find Reports

Select Report Type

Reimbursement Review

Displaying 1426 - 1426 of 1426

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
seladelpar	TBC	seladelpar		primary biliary cholangitis		Pending			SR0899-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 601 - 602 of 602

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1426 - 1450 of 2138

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Vizimpro for Non-Small Cell Lung Cancer – Details	pcodr-provfund-10129-dacomitinib-vizimpro.pdf 10129DacomitinibNSCLC_FnRec_approvedbyChair_Post_NOREDACT_31May2019_final.pdf 10129DacomitinibNSCLC_fnEGR_NOREDACT-ABBREV_Post_31May2019_final.pdf 10129DacomitinibNSCLC_fnCGR_NOREDACT_Post_31May2019_final.pdf 10129DacomitinibNSCLC_InRec_POST04Apr2019_NOREDACT_final.pdf 10129DacomitinibNSCLC_PAGFeedbackSummary_FINAL_Post_31May2019_final.pdf 10129DacomitinibNSCLC_SubmitterFeedback_2019-04-18_Post_31May2019_final.pdf 10129DacomitinibNSCLC_ClinicianFeedback_CCO_2019-04-18_Post_31May2019_final.pdf 10129DacomitinibNSCLC_Patient_Combined_COIs_ForPosting_31May2019_final.pdf 10129DacomitinibNSCLC_Clinician_Combined_COIs_Post_31May2019_final.pdf	Jun 17, 2019	Reimbursement Review		Complete	PC0129-000
doravirine lamuvidine tenofovir disoproxil fumarate	SR0581 Delstrigo - CDEC Final Recommendation May 16, 2019 for posting.pdf SR0581 Delstrigo - Patient Input for Posting.pdf sr0581-delstrigo-cdr-new-combination-report.pdf	Jun 14, 2019	Reimbursement Review		Complete	SR0581-000
isavuconazole	SR0586 Cresemba - CDEC Final Recommendation May 17, 2019_for posting.pdf sr0586-cresemba-clinical-review-report.pdf sr0586-cresemba-pharmacoeconomic-review-report.pdf	Jun 13, 2019	Reimbursement Review		Complete	SR0586-000
Trastuzumab for Breast and Gastric Cancer Biosimilar – Details		Jun 7, 2019	Reimbursement Review		Cancelled	PC0160-000
Rituximab (Truxima) for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar - Details		Jun 7, 2019	Reimbursement Review		Cancelled	PC0184-000
Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details	pcodr-provfund-10151-crizotinib-xalkori-ROS-positive.pdf 10151CrizotinibNSCLC_fnRec_EC_approvedbyChair_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_fnEGR_EC_NOREDACT-ABBREV_Post_23May2019_final.pdf 10151CrizotinibNSCLC_fnCGR_EC_NOREDACT_Post_23May2019_final.pdf 10151CrizotinibNSCLC_inRec_03May2019_approvedbyChair_Post_03May2019_final.pdf 10151CrizotinibNSCLC_PAGFeedbackSummary_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_SubmitterFeedback_2019-05-17_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_PatientFeedback_LCC_2019-05-17_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_ClinicianFeedback_LCC_2019-05-17_Post_23May2019_final_cleaned.pdf 10151CrizotinibNSCLC_Combined_COIs_Post_23May2019.pdf 10151CrizotinibNSCLC_Combined_COI_Post_23May2019_final_Redacted.pdf	Jun 7, 2019	Reimbursement Review		Complete	PC0151-000
Appropriate Pharmacotherapy for Inflammatory Bowel Disease	ho0003-he0018-ibd-ou360.pdf	Jun 6, 2019	Health Technology Review	Technology Review	Completed	HO0003-000 - HE0018-000
Appropriate Pharmacotherapy for Inflammatory Bowel Disease		Jun 5, 2019	Health Technology Review	Technology Review	Completed	HO0003-000 - HE0018-000
Criteria for conducting Environmental Assessments in CADTH HTAs		Jun 5, 2019	Health Technology Review		In Progress	MG0017-000
Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details		May 31, 2019	Reimbursement Review		Withdrawn	PC0169-000
decitabine		May 29, 2019	Reimbursement Review		Not filed	NS0001-000
CADTH Pharmaceutical Reviews Update — Issue 8		May 23, 2019	Reimbursement Review	Pharmaceutical Review Update
Tafinlar & Mekinist in combo Melanoma Adjuvant Therapy – Details	pcodr-provfund_10152_dabrafenib_trametinib_and_tafinlar_mekinist.pdf 10152DabrafenibTrametinibMAT_Final Recc_Approved by Chair_2May2019_REDACT_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_fnCGR_REDACT_Post_03May2019_final.pdf 10152 Dabrafenib-Trametinib MAT_inRec_Approved by Chair_REDACT_Post_07Mar2019_final.pdf 10152DabrafenibTrametinibMAT_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_SubmitterFeedback_2019-03-12_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_ClinicianFeedback_CCO_2019-03-14_Post_03May2019_final.pdf 10152DabrafenibTrametinibMAT_PatientCOI_Combined_Post_03May2019_final_Redacted.pdf 10152DabrafenibTrametinibMAT_ClinicianCOI_Combined_Post_03May2019_final_Redacted.pdf	May 21, 2019	Reimbursement Review		Complete	PC0152-000
Imfinzi for Non-Small Cell Lung Cancer – Details	pcodr_profund_durvalumabImfinzi_nsclc.pdf 10131DurvalumabNSCLC_fnRec_02May2019_approvedbyChair_Post_03May2019_final.pdf 10131DurvalumabNSCLC_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf 10131DurvalumabNSCLC_fnCGR_NOREDACT_Post_03May2019_final.pdf 10131DurvalumabNSCLC_inRec_approvedbyChair_06Mar2019_Post_07Mar2019_final.pdf 10131DurvalumabNSCLC_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf 10131DurvalumabNSCLC_SubmitterFeedback_2019-03-21_Post_03May2019_final.pdf 10131DurvalumabNSCLC_ClinicianFeedback_CCO_2019-03-21_Post_03May2019_final.pdf 10131DurvalumabNSCLC_Combined_PatientCOI_2018-10-05_Post_03May2019_final_Redacted.pdf 10131DurvalumabNSCLC_Combined_ClinicianCOI_Post_03May2019_final_Redacted.pdf	May 21, 2019	Reimbursement Review		Complete	PC0131-000
Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details	pcodr_provfund-10150-ibrance-faslodex-mbc.pdf 10150 PalbociclibFulvestrantMBC_fnRec_2019-05-03_Approved_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_fnCGR_NOREDACT_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_inRec_2019-03-06_ChairApproved_NOREDACT_Post_07Mar2019_final.pdf 10150PalbociclibFulvestrantMBC_PAGFeedbackSummary_FINAL_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_SubmitterFeedback_2019-03-21_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_ClinicianFeedback_CCO_2019-03-22_Post_03May2019_final.pdf 10150PalbociclibFulvestrantMBC_Combined_PatientCOI_RBC_Posting_03May2019_Redacted_final.pdf 10150PalbociclibFulvestrantMBC_Combined_ClinicianICOI_Post_03May2019_final_Redacted.pdf	May 21, 2019	Reimbursement Review		Complete	PC0150-000
filgrastim		May 17, 2019	Reimbursement Review		Cancelled	SE0585-000
Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines	RC1111 Buprenorphine for Opioid Use Disorder During Pregnancy Final.pdf	May 9, 2019	Health Technology Review	Summary with Critical Appraisal	Completed	RC1111-000
cysteamine bitartrate	SR0526_Procysbi_complete_Jan-26-18.pdf SR0526_Procysbi_CL_Report.pdf SR0526_Procysbi_PE_Report.pdf SR0526_Procysbi_Patient_Input.pdf SI0002-procysbi-drug-implementation-advice.pdf	May 8, 2019	Reimbursement Review		Complete	SR0526-000
Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review	Rural Breast Cancer Surgery Programs: A Rapid Qualitative Review	May 3, 2019	Health Technology Review	Rapid Review	Completed	RC1104-000
Zytiga for Prostate Cancer – Details		May 3, 2019	Reimbursement Review		Withdrawn	PC0166-000
Prescription Drug Monitoring Programs: A Rapid Qualitative Review	Prescription Drug Monitoring Programs: A Rapid Qualitative Review	Apr 30, 2019	Health Technology Review	Rapid Review	Completed	RC1097-000
Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details	media:document:d397af7a-2c5f-4887-b25d-c21a007fc947	Apr 29, 2019	Reimbursement Review		Cancelled	PC0180-000
edaravone	sr0573-radicava-clinical-review-report.pdf sr0573-radicava-pharmacoeconomic-review-report.pdf sr0573_radicava-patient-input.pdf sr0573-radicava-cdec-rec-march-29-2019.pdf	Apr 25, 2019	Reimbursement Review		Complete	SR0573-000
Lenvima for Renal Cell Carcinoma – Details	pcodr_profund_lenvatinib_lenvima_rcc_10140.pdf 10140LenvatinibRCC_FnRec_approvedbyChair_Post_04Jan2019_final.pdf 10140LenvatinibRCC_fnCGR_REDACT_Post_04Jan2019_final.pdf 10140LenvatinibRCC_fnEGR_NOREDACT-ABBREV_Post_04Jan2019_final.pdf pcodr_lenvatinib_lenvima_rcc_in_rec.pdf 10140_Lenvatinib_RCC_PAGFeedbackSummary_FINAL_Post_04Jan2019_final.pdf 10140LenvatinibRCC_SubmitterFeedback_2018-11-29_updated_Post_04Jan2019_final.pdf 10140LenvatinibRCC_PatientGroupFeedback_KCC_2018-11-15_Post_04Jan2019_final.pdf 10140LenvatinibRCC_ClinicianFeedback_Combined_Post_04Jan2019_final_Redacted.pdf 10140LenvatinibRCC_COI_KCC_2018-06-22_Post_04Jan2019_draft_Redacted.pdf 10140LenvatinibRCC_Combined_Clinician COIs_Post_04Jan2019_final.pdf	Apr 25, 2019	Reimbursement Review		Complete	PC0140 -000
Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines	RC1092 Buprenorphine for OUD Final.pdf	Apr 24, 2019	Health Technology Review	Summary with Critical Appraisal	Completed	RC1092-000

Provisional Funding Algorithm

Displaying 76 - 81 of 81